Zentalis Pharmaceuticals, Inc. (ZNTL) Form 8-K — Aug 6, 2026
Zentalis Pharmaceuticals reported second quarter 2026 results on August 6, 2026, posting a net loss of $42.3 million, or $0.59 per share, on total operating expenses of $44.4 million, up from $36.1 million a year ago, driven largely by a $7.0 million milestone payment to Recurium IP Holdings and higher DENALI and ASPENOVA clinical costs. Cash, cash equivalents and marketable securities stood at $174.6 million as of June 30, 2026, down from $245.9 million at year-end 2025, which management says funds operations into late 2027 and covers the DENALI Part 2 topline readout expected in the first half of 2027.
Key figures
- Total Assets
- 215330000
- Cash Position
- 174608000
- Shares Outstanding
- 71700000
- Cash Runway
- into late 2027
- Cash Dec31 2025
- $245.9 million
- Net Loss Q2 2025
- -$26.9 million
- Working Capital
- $143.7 million
- Ga Expenses Q2 2026
- $9.2 million (vs $8.4 million Q2 2025)
- Rnd Expenses Q2 2026
- $35.2 million (vs $27.6 million Q2 2025)
- Net Loss Six Months2026
- -$77.6 million
- Recurium Milestone Payment
- $7.0 million (Phase 3 ASPENOVA initiation)
- Denali Part2 Target Enrollment
- ~140 patients at selected dose
- Elahere2025 Us Sales Reference
- $607 million (AbbVie Q4 2025 earnings, cited in deck)
- Cyclin E1 Positive Proc Patients
- ~20,000 (US, EU4, UK, Japan)
- Total Operating Expenses Q2 2026
- $44.4 million (vs $36.1 million Q2 2025)
- Aspenova Phase3 Planned Enrollment
- 420
Price after filing
Close on the filing date to close N calendar days later (from $4.88). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.